^
    Back
    Association details:
    Biomarker:CXCL9 expression
    Cancer:Urothelial Cancer
    Drug Class:PD-L1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Am J Transl Res
    Title:

    The expression panel of CXCL9, GBP5, and IFNG is a potential pan-cancer biomarker to predict immunotherapy response

    Published date:
    07/12/2023
    Excerpt:
    The expression of CXCL9, IFNG, and GBP5 was independently associated with the response to anti-PD-L1 immunotherapy in patients with mUC.